On October 30, 2025 NeoGenomics, Inc. (NASDAQ: NEO), a leading provider of oncology diagnostic solutions that enable precision medicine, reported it will present new research at the International Society of Liquid Biopsy (ISLB) Annual Congress 2025 demonstrating high concordance between its RaDaR ST and RaDaR 1.0 assays for detecting molecular residual disease (MRD) in solid tumors. NeoGenomics will also present on the progress of its NextGen (whole genome-based) MRD research program, as well as three additional posters highlighting the company’s work in liquid biopsy and genomic profiling across solid tumor types.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
The bridging study, "Performance Comparison of RaDaR 1.0 and RaDaR ST Assays for Circulating Tumor DNA Detection Across Solid Tumor Types" (PP.41), evaluated matched samples from 166 patients representing 15 solid tumor types. RaDaR ST demonstrated 97% concordance and maintained equivalent sensitivity with RaDaR 1.0. This study provides analytical confirmation that RaDaR ST maintains the performance of RaDaR 1.0, supporting continuity in MRD assessment as the platform is updated. RaDaR ST is currently covered by Medicare for HR+/HER2- breast cancer (>5 years after diagnosis, recurrence monitoring) and HPV- head and neck carcinoma (adjuvant and recurrence monitoring) and has demonstrated utility across multiple tumor types.
"MRD has become an important part of a patient’s journey for cancer surveillance and monitoring," said Tony Zook, CEO. "This study shows that RaDaR ST delivers equivalent sensitivity as compared to RaDaR 1.0. We are excited to offer clinicians and patients MRD testing optionality with the expected launch of RaDaR ST in Q1 2026. As we continue to invest in novel MRD technologies for the future, the expanding portfolio of MRD solutions will help address unmet needs for sensitive and accurate residual disease detection and monitoring in patients with cancer."
In addition to the RaDaR ST bridging study, NeoGenomics will present four other posters at ISLB:
Performance Characterization of a Novel Whole Genome Sequencing Informed MRD Assay (PP.15), evaluating a whole genome-informed, tumor-specific approach to detect ctDNA at very low levels in solid tumors.
Genomic Profiles of Early-Stage Non-Small Cell Lung Cancer Patients, and Association with Pre-Treatment Blood Circulating Tumor DNA Detection and Levels (PP.74), analyzing genomic features of early-stage lung cancers and investigating the relationship between tumor genomics, ctDNA detectability, and clinical outcomes in these patients.
Validation of NEO │ PanTracer LBx, a Liquid Biopsy Precision Oncology Pan-Solid Tumor Comprehensive Genomic Profiling Assay (PP.05), presenting analytical and clinical validation findings for therapy selection using liquid biopsy.
Non-invasive identification of actionable biomarkers in advanced solid tumors by comprehensive genomic profiling with NEO | PanTracer LBx assay (PP.04), assessing liquid biopsy-based comprehensive genomic profiling to detect actionable variants and support treatment decisions in late-stage cancers.
These presentations contribute to NeoGenomics’ growing body of research in liquid biopsy for MRD detection and genomic profiling. The findings reinforce the company’s strategy to advance next-generation molecular testing platforms and expand the role of ctDNA in clinical research and patient management.
(Press release, NeoGenomics Laboratories, OCT 30, 2025, View Source [SID1234657180])